UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
Commission File No. 001-12671
NOTIFICATION OF LATE FILING
(Check One): |_| Form 10-K |_| Form 10-KSB |_| Form 20-F |_| Form 11-K
|X| Form 10-QSB |_| Form N-SAR
For Period Ended: September 30, 2005
-------------------
|_| Transition Report on Form 10-K
|_| Transition Report on Form 10-KSB
|_| Transition Report on Form 20-F
|_| Transition Report on Form 11-K
|_| Transition Report on Form 10-Q
|_| Transition Report on Form N-SAR
For the Transition Period Ended:
--------------------------------------------------------------------------------
Read Intructions (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
--------------------------------------------------------------------------------
If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
--------------------------------------------------------------------------------
PART I - REGISTRANT INFORMATION
--------------------------------------------------------------------------------
Full Name of Registrant
Kiwa Bio-Tech Products Group Corporation
--------------------------------------------------------------------------------
Former Name if Applicable
Tintic Gold Mining Company
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Address of Principal Executive Office Street and Number
415 West Foothill Blvd., Suite 206
--------------------------------------------------------------------------------
City, State and Zip Code
Claremont, California 91711-2766
PART II - RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate.)
(a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
|X| (b) The subject annual report, semi-annual report, transition report on
Form 10-K, Form 10-KSB, Form 20-F, Form 11-K or Form N-SAR, or
portion thereof will be filed on or before the fifteenth calendar
day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q, or portion thereof will be
filed on or before the fifth calendar day following the prescribed
due date; and
(c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
PART III - NARRATIVE
State below in reasonable detail why the Form 10-K, 10-KSB, 20-F, 11-K 10-QSB,
N-SAR or the transition report portion thereof could not be filed within the
prescribed time period.
Kiwa Bio-Tech Products Group Corporation (the "Registrant") could not
complete the filing of its Quarterly Report on Form 10-QSB for the period ended
September 30, 2005 due to a delay in obtaining and compiling information
required to be included in the Registrant's Form-10QSB, which delay could not be
eliminated by the Registrant without unreasonable effort and expense. In
accordance with Rule 12b-25 of the Securities Exchange Act of 1934, the
Registrant will file its Form 10-QSB no later than the 5th calendar day
following the prescribed due date.
PART IV - OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Yvonne Wang 909 626-2358
----------- ------------ -----------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that
the registrant was required to file such report(s) been filed? If the
answer is no, identify report(s).
|X| Yes |_| No
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected
by the earnings statements to be included in the subject report or portion
thereof?
|X| Yes |_| No
If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
Kiwa Bio-Tech Products Group Corporation
--------------------------------------------------------------------------------
(Name of Registrant as Specified in Charter)
Date November 14, 2005 By /s/ Wei Li
------------------- --------------------------------------------
Wei Li
Chief Executive Officer
INSTRUCTION: The form may be signed by an executive officer of the registrant or
by any other duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If the
statement is signed on behalf of the registrant by an authorized representative
(other than an executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.
--------------------------------------------------------------------------------
ATTENTION
--------------------------------------------------------------------------------
Intentional misstatements or omissions of fact constitute Federal Criminal
Violations (see 18 U.S.C. 1001).
Explanation of Anticipated Change
On March 12, 2004, pursuant to an Agreement and Plan of Merger (the "Merger
Agreement") dated as of March 11, 2004, by and among the Registrant (formerly
named Titinc Gold Mining Company), TTGM acquisition Corporation, a Utah
corporation and wholly-owned subsidiary of the Registrant ("Merger Sub"), and
Kiwa Bio-Tech Products Group Ltd., a privately-held corporation organized in the
British Virgin Islands ("Kiwa Bio-Tech"), Merger Sub merged with and into Kiwa
Bio-Tech with Kiwa Bio-Tech surviving as a wholly-owned subsidiary of the
Registrant (the"Merger"). On March 17, 2004, the Registrant changed its name to
Kiwa Bio-Tech Products Group Corporation.
Prior the Merger, the Registrant did not conduct any significant business or
operations, and had only nominal revenues for the three months ended March 31,
2004. As a consequence of the Merger, Kiwa Bio-Tech's business and operations
comprise the overwhelming majority of the Registrant's business and operations.
The Registrant incurred a net loss of $1,650,247 for the three-month period
ended March 31, 2004 ( on a consolidated basis) and expects to report a net loss
of approximately $433,533 for the thre-month period ended September 30, 2005.